Replimune Group Inc (REPL)

$4.09 +0.35 (9.36%)
Market Cap 308.82M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 9,615,900
Avg Vol 6,366,268
Day's Range N/A - N/A
Shares Out 82.57M
Stochastic %K 83%
Beta 0.12
Analysts Hold
Price Target $2.20

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
beachsidefreddy
beachsidefreddy May. 13 at 12:00 PM
$REPL do you idiots know they released almost all of their employees? THEY ARE DONE< FINISHED
0 · Reply
Dorps332
Dorps332 May. 13 at 11:17 AM
$REPL question is if th y do resubmit how long before the FDa actually looks into it again
1 · Reply
jconnors7
jconnors7 May. 13 at 10:53 AM
$REPL ”A rising tide lifts all ships.” Meaning: i own both REPL and IOVA and plan on both being successful and both going much higher. Why people bash one or the other here I do bot know. I own AI, semis, crypto. They all go up together when supported Why cant IOVA and REPL. “A rising tide lifts all ships.”
1 · Reply
Hero2Zero
Hero2Zero May. 13 at 10:35 AM
$REPL https://download.open.fda.gov/crl/CRL_BLA125827_20260410.pdf For those wanting to actually read the CRL and see the laundry list of problems for themselves. When the pumpers cite company published effectiveness numbers, just realize the trial investigators and the company went out of their way (circumventing third party oversight and trial protocol) to pump their numbers. They were caught red-handed by the FDA review team and explicitly called out.
1 · Reply
gazza01
gazza01 May. 13 at 10:07 AM
$REPL I looked at the CRLs and there really are major problems. Maybe unfair that the FDA didn't raise them sooner, but they are real. I don't think the US should drop its high standards.
1 · Reply
Pointkenya
Pointkenya May. 13 at 8:27 AM
$REPL Lets do this!!
1 · Reply
History101
History101 May. 13 at 1:40 AM
$REPL $QURE good article, more pressure to let patients with rare diseases, or hopeless terminal diseases, try whatever they want to combat their illnesses... https://www.theblaze.com/columns/opinion/the-fda-seems-to-care-more-about-celebrities-than-sick-americans
0 · Reply
TopCharts
TopCharts May. 12 at 10:32 PM
$REPL and this news just in they still have 2 CRLs zero approved product and zero revenue, CEO just announced:
1 · Reply
Kale
Kale May. 12 at 10:20 PM
$REPL doubt they let the FDA make them lose their money As of late 2025 filings: * BlackRock owned about 6.07 million shares of Replimune, representing roughly 7.35% of the company. * Other major holders include: * Baker Bros. Advisors (~12–13%) * T. Rowe Price (~10%) * RTW Investments (~8.6%) * Vanguard (~4.6%)
3 · Reply
mikesterz7
mikesterz7 May. 12 at 9:47 PM
$REPL $QURE Marty Makary has resigned as commissioner of the Food and Drug Administration after weeks of mounting pressure from the Trump administration. 🔥🔥🔥
0 · Reply
Latest News on REPL
Replimune jumps on news FDA chief behind RP1 rejection may be removed

2026-05-08T18:59:46.000Z - 4 days ago

Replimune jumps on news FDA chief behind RP1 rejection may be removed

FDA Commissioner Makary defends agency's decision on Replimune's drug

May 5, 2026, 10:58 AM EDT - 7 days ago

FDA Commissioner Makary defends agency's decision on Replimune's drug

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 22, 2026, 12:56 PM EDT - 20 days ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Replimune rises after Wall Street Journal editorial defending RP1

2026-04-22T15:00:52.000Z - 20 days ago

Replimune rises after Wall Street Journal editorial defending RP1

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 13, 2026, 11:46 AM EDT - 4 weeks ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Replimune downgraded to Neutral from Outperform at Wedbush

2026-04-13T10:48:47.000Z - 4 weeks ago

Replimune downgraded to Neutral from Outperform at Wedbush

Replimune downgraded to Market Perform from Outperform at Leerink

2026-04-13T10:43:51.000Z - 4 weeks ago

Replimune downgraded to Market Perform from Outperform at Leerink

Replimune downgraded to Sell from Buy at H.C. Wainwright

2026-04-13T10:10:29.000Z - 4 weeks ago

Replimune downgraded to Sell from Buy at H.C. Wainwright

Replimune downgraded to Underweight from Neutral at JPMorgan

2026-04-13T09:05:07.000Z - 4 weeks ago

Replimune downgraded to Underweight from Neutral at JPMorgan

Replimune downgraded to Hold from Buy at Jefferies

2026-04-12T23:15:05.000Z - 4 weeks ago

Replimune downgraded to Hold from Buy at Jefferies

Replimune downgraded to Underperform from Market Perform at BMO Capital

2026-04-10T22:00:16.000Z - 4 weeks ago

Replimune downgraded to Underperform from Market Perform at BMO Capital

Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-04-10T21:20:15.000Z - 4 weeks ago

Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

Replimune says FDA’s CRL for RP1 ‘disappointing’

2026-04-10T21:10:50.000Z - 4 weeks ago

Replimune says FDA’s CRL for RP1 ‘disappointing’

Replimune says FDA ‘appears to have contradicted their positions’ in CRL

2026-04-10T21:10:15.000Z - 4 weeks ago

Replimune says FDA ‘appears to have contradicted their positions’ in CRL

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 5:02 PM EDT - 4 weeks ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-04-10T20:20:57.000Z - 4 weeks ago

Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

Replimune downgraded to Neutral at Piper Sandler after second CRL

2026-04-10T19:51:23.000Z - 4 weeks ago

Replimune downgraded to Neutral at Piper Sandler after second CRL

Replimune downgraded to Neutral from Overweight at Piper Sandler

2026-04-10T19:40:18.000Z - 4 weeks ago

Replimune downgraded to Neutral from Overweight at Piper Sandler

Replimune CRL positive for Iovance in near-term, says Chardan

2026-04-10T17:43:13.000Z - 4 weeks ago

Replimune CRL positive for Iovance in near-term, says Chardan

IOVA

US FDA declines to approve Replimune's drug for advanced skin cancer

Apr 10, 2026, 11:24 AM EDT - 4 weeks ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 2 months ago

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Replimune to Present at Two Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 2 months ago

Replimune to Present at Two Upcoming Investor Conferences

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 3 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 4 months ago

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 5 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 6 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 6 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 7 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 7 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 8 months ago

Replimune Provides Update Following Type A Meeting with FDA

Replimune Group Transcript: AGM 2025

Sep 3, 2025, 11:30 AM EDT - 8 months ago

Replimune Group Transcript: AGM 2025

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Replimune Announces Type A Meeting Scheduled with FDA

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 10 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 10 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 10 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 10 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 10 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 10 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Group Transcript: Investor Day 2025

Jun 24, 2025, 10:00 AM EDT - 11 months ago

Replimune Group Transcript: Investor Day 2025

Replimune Group Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 4:20 PM EDT - 1 year ago

Replimune Group Transcript: Jefferies Global Healthcare Conference 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 1 year ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

beachsidefreddy
beachsidefreddy May. 13 at 12:00 PM
$REPL do you idiots know they released almost all of their employees? THEY ARE DONE< FINISHED
0 · Reply
Dorps332
Dorps332 May. 13 at 11:17 AM
$REPL question is if th y do resubmit how long before the FDa actually looks into it again
1 · Reply
jconnors7
jconnors7 May. 13 at 10:53 AM
$REPL ”A rising tide lifts all ships.” Meaning: i own both REPL and IOVA and plan on both being successful and both going much higher. Why people bash one or the other here I do bot know. I own AI, semis, crypto. They all go up together when supported Why cant IOVA and REPL. “A rising tide lifts all ships.”
1 · Reply
Hero2Zero
Hero2Zero May. 13 at 10:35 AM
$REPL https://download.open.fda.gov/crl/CRL_BLA125827_20260410.pdf For those wanting to actually read the CRL and see the laundry list of problems for themselves. When the pumpers cite company published effectiveness numbers, just realize the trial investigators and the company went out of their way (circumventing third party oversight and trial protocol) to pump their numbers. They were caught red-handed by the FDA review team and explicitly called out.
1 · Reply
gazza01
gazza01 May. 13 at 10:07 AM
$REPL I looked at the CRLs and there really are major problems. Maybe unfair that the FDA didn't raise them sooner, but they are real. I don't think the US should drop its high standards.
1 · Reply
Pointkenya
Pointkenya May. 13 at 8:27 AM
$REPL Lets do this!!
1 · Reply
History101
History101 May. 13 at 1:40 AM
$REPL $QURE good article, more pressure to let patients with rare diseases, or hopeless terminal diseases, try whatever they want to combat their illnesses... https://www.theblaze.com/columns/opinion/the-fda-seems-to-care-more-about-celebrities-than-sick-americans
0 · Reply
TopCharts
TopCharts May. 12 at 10:32 PM
$REPL and this news just in they still have 2 CRLs zero approved product and zero revenue, CEO just announced:
1 · Reply
Kale
Kale May. 12 at 10:20 PM
$REPL doubt they let the FDA make them lose their money As of late 2025 filings: * BlackRock owned about 6.07 million shares of Replimune, representing roughly 7.35% of the company. * Other major holders include: * Baker Bros. Advisors (~12–13%) * T. Rowe Price (~10%) * RTW Investments (~8.6%) * Vanguard (~4.6%)
3 · Reply
mikesterz7
mikesterz7 May. 12 at 9:47 PM
$REPL $QURE Marty Makary has resigned as commissioner of the Food and Drug Administration after weeks of mounting pressure from the Trump administration. 🔥🔥🔥
0 · Reply
Kale
Kale May. 12 at 9:28 PM
$REPL company cannot reach the mountain top alone. They will need to be bought out which will likely be from one of its partners.
1 · Reply
History101
History101 May. 12 at 9:28 PM
$REPL LOL making it on the Fast Money news just a few minutes ago:
1 · Reply
Kale
Kale May. 12 at 9:27 PM
$REPL 40% short interest. Expect institutional investors to buy more at this level
1 · Reply
Kale
Kale May. 12 at 9:09 PM
$REPL this is worth at least $500-700 million. May the shorts dig their graves with this company
0 · Reply
Kale
Kale May. 12 at 8:55 PM
$REPL by 2050 half 50% of the population is expected to get cancer during their lifetime. May it be primarily on shorts that try to destroy good treatment options.
1 · Reply
Kale
Kale May. 12 at 8:44 PM
$REPL https://www.msn.com/en-us/money/news/replimune-co-founder-calls-fda-rejection-of-melanoma-drug-unfair/vi-AA20MUqR
0 · Reply
Charlie_Omaha
Charlie_Omaha May. 12 at 8:40 PM
$IOVA How do you trade nearly 150 million shares with ER and $REPL fiasco and end up in red. How? Wayne and Fred belong in prison. Wayne Rothbaum is an insider criminal along with incompetent Fred. Big pharma could be paying Wayne to ruin Iovance to protect their revenue.
1 · Reply
History101
History101 May. 12 at 8:38 PM
$REPL check out $SLS , moving big after hours on great trial news. GLTALs!!
0 · Reply
Kale
Kale May. 12 at 8:32 PM
$REPL Mechanistically they may also appeal to different patient populations: * RP1 may work best in patients with injectable lesions and enough immune responsiveness to synergize with PD-1 blockade. * Lifileucel may be more attractive for highly refractory disease where harvesting and expanding tumor-reactive T cells can overcome immune resistance. One additional nuance: RP1 could eventually fit earlier in treatment sequencing because it is comparatively easy to administer, while TIL therapy is usually reserved for fit patients who can tolerate lymphodepletion and IL-2. From an investment perspective: * Iovance Biotherapeutics currently has the stronger commercial/regulatory position because Amtagvi is already marketed. * Replimune Group has higher platform uncertainty but potentially broader future applicability if RP1 or RP2 eventually succeed.
1 · Reply
Kale
Kale May. 12 at 8:16 PM
$REPL Most important RP2 clinical data so far Metastatic uveal melanoma (eye melanoma) This is the dataset that generated the most attention. At ASCO 2024: * RP2 alone or with nivolumab in metastatic uveal melanoma showed: * ORR 29.4% * Disease control rate 58.8% * durable responses * activity even in liver metastases * generally favorable tolerability. That is notable because metastatic uveal melanoma is notoriously resistant to immunotherapy. For context: * historical checkpoint inhibitor response rates are usually very low (~5–15%) * median survival is poor once metastatic. This is why RP2 became one of the more interesting oncolytic virus programs in oncology. Why RP2 may matter more scientifically than RP1
1 · Reply
Kale
Kale May. 12 at 8:14 PM
$REPL most dont know that the company’s strongest asset is likely RP2. Likely they will be bought out for 1.5-2 billion with royalties. FDA is likely corrupt and they constantly try to crush small pharmaceutical companies on the behest of big Pharma. This company meets a big unmet need
0 · Reply
History101
History101 May. 12 at 8:04 PM
$REPL and you don't work for the FDA now either... https://stocktwits.com/news-articles/markets/equity/repl-stock-nosedives-as-fda-commissioner-stands-firm-against-melanoma-treatment/cZQD5waRe9N
0 · Reply